[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stimulant-use\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stimulant-use":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,75,101,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100644752","phase-2-leveraging-mhealth-to-promote-opioid-use-recovery-and-mental-health-among-residents-of-a-medium-sized-midwestern-city-100644752",false,"NCT07673380","Leveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City","Leveraging mHealth to Promote Recovery From Opioid Use Disorder and Commonly Occurring Mental Health Disorders Among Residents of a Medium-Sized Midwestern City","Inclusion Criteria:\n\n* Have a history of opioid and\u002For stimulant use\n* Identify as Black and\u002For African American\n* Seek treatment at local substance use treatment centers\n* Fluent in English\n* U.S. resident\n* 18 years of age or older at the time of data collection.\n\nExclusion Criteria:\n\n* Self-reported cognitive impairment that would limit ability to participate in research.","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The sequential trial compares recovery and mHealth engagement outcomes among Black participants who participated in the mHealth intervention uMAT-R or uMAT-R + enhanced community engagement. The mHealth intervention seeks to support people in various stages of recovery who are also seeking other forms of substance use treatment. Participants are recruited from community-based substance use treatment facilities and recovery services. Participants must be adults who have or are currently using opioids and\u002For stimulants.",[26,27,28],"Opioid Use","Stimulant Use","Depression and Anxiety Symptoms",[30,31],"Digital health","Community engagement","RECRUITING","2026-06-22",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":36},"2025-08-31",{"date":40,"type":20},"2027-02-28",{"name":42,"class":43},"Washington University School of Medicine","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100578667","project-neuroartemis-100578667","NCT06814275","Project neuroARTEMIS","Project ARTEMIS: A Mechanistic Clinical Trial of Neuroimmune Pathways.","Inclusion Criteria:\n\n* 18-59 years old\n* Weekly use of stimulants reported in the past month or a score of 4 or more on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)\n* Confirmed HIV diagnosis\n* Current receipt of daily oral antiretroviral therapy (ART) medication\n* English fluency\u002Fliteracy\n\nExclusion Criteria:\n\n* Acute brain infection (e.g., neurosyphilis, toxoplasmosis)\n* Acutely symptomatic bipolar I or psychotic disorder\n* Prescription for immunomodulatory medications or other immunotherapy\n* Any MRI contraindications\n* If applicable, on antidepressant medication regimen for at least 2 months","59 Years",{"count":54,"type":20},189,[56],"NA","The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.",[27,59,60],"Human Immunodeficiency Virus (HIV)","Depression",[62,63,64,65],"HIV","Stimulant use","substance abuse","chronic stress","2025-09-10",{"date":68,"type":36},"2025-09-11",{"date":70,"type":36},"2025-04-29",{"date":72,"type":20},"2028-12-31",{"name":74,"class":43},"Wake Forest University Health Sciences",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100395218","neuromodulation-and-cognitive-training-for-substance-use-disorders-100395218","NCT04426214","Neuromodulation and Cognitive Training for Substance Use Disorders","Inclusion Criteria:\n\n* Abstinent from any substance or alcohol use (excluding caffeine or nicotine) for a minimum of 3 weeks at study enrollment\n* Has the intention to remain in their treatment program(s) until the end of the intervention portion of the study.\n* Able to provide written consent and comply with study procedures.\n* Meets the MINI 7 diagnostic criteria for either stimulant use disorder (SUD) or alcohol use disorder (AUD).\n\nExclusion Criteria:\n\n* Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, HIV)\n* Over 9 months of abstinence from substance use\n* A head injury resulting in a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI)\n* Presence of a condition that would render study measures difficult or impossible to administer or interpret\n* Age outside the range of 18 to 65\n* Primary current substance use disorder diagnosis (according to MINI 7 diagnostic criteria) for a substance other than stimulant or alcohol, except for caffeine or nicotine (Nicotine use will be recorded but is not exclusionary)\n* Entrance to the treatment program under a court mandate. (i.e. legally incarcerated)\n* History of ECT or cortical energy exposure within the past 6 months, including participation in any other neuromodulation studies","65 Years",{"count":83,"type":20},80,[56],"The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. This study is testing a new intervention, namely tDCS-Augmented Cognitive Training, to engage these brain biomarkers to improve cognition and improve treatment outcomes.",[27,87],"Alcohol Use Disorder",[89,90,91],"tDCS","Cognitive Training","Plasticity","2025-08-25",{"date":94,"type":36},"2025-08-26",{"date":96,"type":36},"2021-07-16",{"date":98,"type":20},"2026-09-01",{"name":100,"class":43},"University of Minnesota",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":44},"100548683","accelerated-rtms-for-substance-use-disorder-and-depression-100548683","NCT06424184","Accelerated rTMS for Substance Use Disorder and Depression","Substance Use Disorder Treatment With Accelerated Repetitive Transcranial Magnetic Stimulation for Depression (START-D)","Inclusion Criteria:\n\n1. Be aged 18-65 years, inclusive.\n2. Be able to sufficiently understand, speak, and read English to provide informed consent and ask relevant questions, and be willing to comply with all study procedure instructions.\n3. Self-report stimulant use (cocaine, methamphetamine, or prescription stimulants) at least 10 days in the 30-day period prior to consent.\n4. Have a diagnosis of moderate or severe Cocaine or Methamphetamine Use Disorder (CUD\u002FMUD) or other Stimulant Use Disorder over the past 12 months (as determined by the MINI International Neuropsychiatric Interview).\n5. Have a PHQ9 of greater than or equal to five (5).\n6. Be willing to provide urine samples, EEGs, and ECGs.\n7. Be willing to use appropriate birth control method during the treatment phase of the study, if individual is of childbearing potential.\n\nExclusion Criteria:\n\n1. Have a current pattern of alcohol, benzodiazepine, or other sedative\u002Fhypnotic use that would preclude safe participation in the study, as determined by the PI or their designee.\n2. Have a history of a serious medical disorder that, in the opinion of the PI or their designee, would make it unsafe to participate in the study or may prevent collection of study data (e.g., disabling terminal diagnosis for which hospice care is being sought; serious illness requiring systemic treatment and\u002For hospitalization until participant either completes therapy and\u002For is clinically stable on therapy, in the opinion of the PI or their designee, prior to study entry).\n3. Have a documented history of unprovoked seizure (lifetime) or any seizure in the past 6 months.\n4. Have a documented history of brain lesion(s) and\u002For tumor(s).\n5. Have metal implants or non-removable metal objects above the neck.\n6. Current pregnancy as determined by a urine screening.\n7. Current or lifetime manic or hypomanic episode, defined by MINI diagnostic interview.\n8. Current psychotic disorder.\n9. Are a prisoner or in police custody at the time of eligibility screening.",{"count":109,"type":20},40,[56],"This study is a small open-label feasibility trial of an accelerated course of repetitive transcranial magnetic stimulation (rTMS) for individuals with depression and stimulant use disorder \\[including methamphetamine or cocaine use disorder (MUD\u002FCUD)\\].",[27,60],"2025-07-28",{"date":115,"type":36},"2025-07-31",{"date":117,"type":36},"2024-06-25",{"date":119,"type":20},"2027-06",{"name":121,"class":43},"University of Texas Southwestern Medical Center",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":129,"sex":16,"minAge":17,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":139,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":44},"100357561","phase-2-acute-effects-of-stimulant-medication-in-college-students-with-adhd-100357561","NCT03935646","Acute Effects of Stimulant Medication in College Students With ADHD","Acute Effects of Prescription Stimulant Medication on Cognition and Mood in College Students With and Without ADHD","Inclusion Criteria:\n\n* Be currently enrolled either full time or part time as an undergraduate in a 2-year or 4-year college\n* Be between the ages of 18-29\n* Be a native English speaker\n* ADHD Participants: Must report a prior diagnosis of ADHD and self-report five or more inattention (IA) symptoms on the DSM-5 Symptom Checklist on the pre-screener.\n* Healthy Participants: Must disavow ever being diagnosed with ADHD, report 3 or fewer IA symptoms and 3 or fewer hyperactivity\u002Fimpulsivity (HI) symptoms on the DSM-5 ADHD Symptom Checklist in the pre-screener and are an age and sex match of an ADHD group participant\n\nExclusion Criteria:\n\n* Not meeting any of the above stated inclusion criteria\n* Any contraindications for physical exercise placing the participant at moderate or high-risk. This includes the following:\n\n  1. Participants will be excluded if they report having an acute or uncontrolled disease (cardiovascular, pulmonary, neurological, endocrine, musculoskeletal, immunological).\n  2. Participants will be excluded if they are non-ambulatory or rely on walking aids for ambulation.\n  3. Participants will be excluded who chronically manage asthma or another respiratory condition or require using an inhaler to complete exercise.\n  4. Participants will be excluded if they experience uncontrolled or current problems with syncope (loss of consciousness or fainting) or postural hypotension.\n  5. Participants will be excluded if they have ever had a stroke, aneurysm, or transient ischemic attack (TIA).\n  6. Participants will be excluded if they have exercise or physical activity restrictions imposed by a health provider.\n  7. Participants will be excluded by the medical director due to possible underlying disease\u002Fcondition or risk.\n  8. Participants will be excluded if they are pregnant (determined by a urine pregnancy test), are attempting to become pregnant, or are currently breastfeeding will also be excluded (stated above).\n  9. Participants will be excluded for any current use of other psychotropic drugs (e.g., SSRIs, SNRIs, sedatives; stated above).\n* Any contraindications for stimulant medication use placing the participant at moderate or high-risk. This includes the following:\n\n  1. Participants will be excluded if they have ever been diagnosed with seizure disorder, high blood pressure, glaucoma, gastrointestinal hypermotility disorder (e.g., IBS), diabetes, hypoglycemia, cardiac problems (e.g., heart disease), or thyroid problems.\n  2. Participants will be excluded if they have ever been diagnosed with a bipolar disorder (e.g., Bipolar I or Bipolar II), a psychotic disorder (e.g., schizophrenia), a sleep disorder (e.g., narcolepsy), an eating disorder (e.g., bulimia nervosa), or a severe substance use disorder (e.g., endorsing six or more symptoms of a substance use disorder according to the DSM-5). Participants will also be excluded if they report a past year diagnosis of major depressive disorder, panic disorder, generalized anxiety disorder, or any substance use disorder.\n  3. Participants will be excluded if they report any prior treatment for substance use (e.g. rehabilitation for alcohol or other substance use). Additionally, participants will be excluded if they do not agree to abstain from illicit or addictive drugs and marijuana use for the duration of the study beginning with the eligibility assessment.\n  4. Participants will be excluded if they experience uncontrolled or current problems with syncope (e.g., loss of consciousness or fainting) or postural hypotension.\n  5. Participants will be excluded if they are pregnant (determined by a urine pregnancy test), are attempting to become pregnant, or are currently breastfeeding.\n  6. Non-ADHD participants will be excluded if they have ever engaged in non-prescription stimulant use.\n  7. ADHD participants who are currently prescribed a prescription stimulant will be asked not to take their medication the day prior to and day of any study visits. They will be excluded if they are not comfortable with abstaining.\n  8. Participants will be excluded for any current use of other psychotropic drugs (e.g., SSRIs, SNRIs, sedatives) or non-stimulant ADHD medication (i.e., Strattera).\n  9. Participants will be excluded for any current use of any other prescription medication that could interact negatively with Adderall (e.g., neurological and blood-pressure drugs, antihistamines).\n  10. They will also be excluded for current use of high levels of caffeine consumption (e.g., daily use more than 600mg\u002Fday or about six 8-oz. cups of coffee). Daily use is defined as 5 or more days per week for the last month.\n  11. Participants who are using other over-the-counter-substances that could interact negatively with Adderall (e.g., dietary supplements, weight-loss pills, and low-to-moderate levels of caffeine consumption, antihistamines) will be asked to abstain from use for at least 12-hours prior to lab visits. They will be excluded if they are not comfortable with abstaining.\n  12. Participants will be excluded if they report current nicotine use (i.e., 5 or more cigarettes per day), daily vaping (i.e., e-cigarettes), smokeless tobacco (i.e., chewing tobacco), nicotine gum, and\u002For nicotine patches use in the past month.\n  13. Participants will be excluded if they experienced a concussion within the past 6 months, have experienced two or more concussions in their lifetime, or have a history of traumatic brain injury.\n  14. Participants will be excluded if they have ever had a stroke, aneurysm, or transient ischemic attack (TIA).\n  15. Participants will be excluded if they are unwilling to ingest a prescription stimulant medication (Adderall) or placebo in the lab.",true,"29 Years",{"count":109,"type":20},[23],"The investigators will examine the acute effects of stimulant medication on executive functioning. The rationale for the proposed study is to examine the efficacy of stimulants for college students with ADHD and help prevent stimulant misuse among college students without ADHD. The working hypothesis is that stimulants, compared to baseline and placebo conditions, will improve executive functioning for college students with ADHD but not for college students without ADHD. Improvements on executive functioning measures (e.g., CPT-IP, Spatial Span) will be examined through 2 (ADHD vs. non-ADHD) x 3 (Baseline, Placebo, Stimulant) repeated measures ANOVAs. Follow-up analyses will include paired comparisons.\n\nExpected outcomes are to confirm these hypotheses and demonstrate the need for further study of stimulants. If confirmed, the results will provide pilot data for a larger NIH grant proposal aimed at further examining the acute effects of stimulants (i.e., improved cognitive functioning with stimulants) and comparing them to the acute effects of physical exercise (i.e., improved cognitive functioning immediately after exercise). The investigators expect this outcome to have an important positive impact because it can help support stimulant medication as an effective treatment for college students with ADHD (DuPaul et al., 2012). Additionally, demonstration that stimulants do not improve executive functioning for college students without ADHD can be used to help prevent and discourage stimulant misuse and diversion on college campuses (Hartung et al., 2013).",[135,27,136,137,138],"Attention Deficit Hyperactivity Disorder","Working Memory","Change in Sustained Attention","Mood",[135,27,136,137,138],"2024-06-07",{"date":142,"type":36},"2024-06-10",{"date":144,"type":36},"2020-02-11",{"date":146,"type":20},"2025-06-30",{"name":148,"class":43},"University of Wyoming"]